ABD957
Based on 3 publication(s) in Google Scholar
ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC50 of 0.21 μM for ABHD17B. ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.14%
- CAS. Nr.: 3007772-60-0
- Formel: C27H36F3N7O5S
- Molecular Weight:627.68
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ABD957
More
Biologische Aktivität
IC50: 0.21 µM (ABHD17B)[1]
ABD957 (500 nM; pretreated for 1 h) attenuates N-Ras depalmitoylation in AML cells[1].
ABD957 (0.11 nM-10 μM; 72 h) blocks the signaling and proliferation of NRAS-mutant leukemia cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:OCI-AML3, THP1, HL60, NB-4 and NOMO1 cells
-
Concentration:0.1, 1, 10, 100, 1000, 10000 nM
-
Incubation Time:72 hours
-
Result:Reduced the growth of NRAS-mutant AML cell lines (OCI-AML3, THP1 and HL60), but not KRAS mutant cell lines (NB-4 and NOMO1).
Chemical Information
-
CAS. Nr. 3007772-60-0
-
Appearance Solid
-
Molecular Weight 627.68
-
Formel C27H36F3N7O5S
-
Color White to off-white
-
SMILES
C[C@H]1CN(CCN1C(N2C=CC(S(=O)(N(C)C)=O)=N2)=O)CC3=C(C=C(C=C3)C(F)(F)F)N4C5CCC4CN(C5)CC(O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Drug Resist Updat
Palmitoylation modification of SPI1 promotes nasopharyngeal carcinoma radioresistance through inhibiting c-CBL-mediated ubiquitination and degradation. [Abstract]2026 May:86:101374. PMID: 41691772 -
Cell Discov
ASCT2 palmitoylation regulated by JNK1-ZDHHC14 axis orchestrates glutamine metabolism and NSCLC progression. [Abstract]2026 Feb 24;12(1):13. PMID: 41730846 -
Adv Sci (Weinh)
Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2. [Abstract]2023 Oct;10(28):e2302130. PMID: 37544908
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (159.32 mM; ultrasonic and warming and heat to 160°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (7.97 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (7.97 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5932 mL | 7.9658 mL | 15.9317 mL | 39.8292 mL |
| 5 mM | 0.3186 mL | 1.5932 mL | 3.1863 mL | 7.9658 mL | |
| 10 mM | 0.1593 mL | 0.7966 mL | 1.5932 mL | 3.9829 mL | |
| 15 mM | 0.1062 mL | 0.5311 mL | 1.0621 mL | 2.6553 mL | |
| 20 mM | 0.0797 mL | 0.3983 mL | 0.7966 mL | 1.9915 mL | |
| 25 mM | 0.0637 mL | 0.3186 mL | 0.6373 mL | 1.5932 mL | |
| 30 mM | 0.0531 mL | 0.2655 mL | 0.5311 mL | 1.3276 mL | |
| 40 mM | 0.0398 mL | 0.1991 mL | 0.3983 mL | 0.9957 mL | |
| 50 mM | 0.0319 mL | 0.1593 mL | 0.3186 mL | 0.7966 mL | |
| 60 mM | 0.0266 mL | 0.1328 mL | 0.2655 mL | 0.6638 mL | |
| 80 mM | 0.0199 mL | 0.0996 mL | 0.1991 mL | 0.4979 mL | |
| 100 mM | 0.0159 mL | 0.0797 mL | 0.1593 mL | 0.3983 mL |
ABD957 Related Classifications
HY-142161 Related Classifications
Powered by Bioz